This 1-day, Virtual Summit presented by ADInstruments and InsideScientific addressed the latest trends and technology for preclinical cardiovascular research, research case studies from leading academic and industry scientists, and best practice tips & tricks to help advance your methodology and workflows.
In this episode of Expert Answers, Dr. Jack Guralnik and Dr. Charlotte Peterson answer questions about sarcopenia, the physiological mechanisms underlying the disease, and the current avenues of treatment and assessment.
Experts discuss dyadic experiments, highlighting why equipment should be unobtrusive, the importance of tightly synchronized data, and how to select the right equipment based on your experimental objective.
Dr. Matt Kaeberlein, a Professor at the University of Washington School of Medicine, answers questions from a recent webinar that focused on translational geroscience, the drug rapamycin to target biological aging, and the Dog Aging Project.
Lee Stoner, PhD and Gabriel Zieff answer questions about utilizing Pulse Wave Velocity (PWV) in a variety of different research applications, and discuss the methods they use to record high-quality, repeatable data.
In this episode of Expert Answers, Dr. Dee Silverthorn answers questions on how the sudden appearance of the global pandemic of COVID-19 provides a unique opportunity to show students science in action.
In this webinar, Dr. Joy Wu will review the pathophysiology of bone loss with aging, in particular the imbalance between bone formation by osteoblasts and bone resorption by osteoclasts. She will discuss stem cell sources of osteoblasts, anabolic signaling pathways, and targeting inflammation and senescence.
Dr. Charlotte Peterson and Dr. Jack Guralnik will discuss the challenges of sarcopenia. They will define the disease and provide an in depth overview of the underlying mechanisms of pathology. They will then share some potential therapeutic interventions and disease outcomes for patients.
During this webinar, Dr. Matt Kaeberlein provides an overview of translational geroscience, which he believes will become the paradigm for the practice of medicine in the 21st century. He also discusses his recent work with one such intervention, the drug rapamycin, and its potential to enhance healthspan in companion dogs and people.